Last reviewed · How we verify
Benzbromaron
At a glance
| Generic name | Benzbromaron |
|---|---|
| Sponsor | Amsterdam UMC, location VUmc |
| Target | Eyes absent homolog 2, Eyes absent homolog 3, ATP-binding cassette sub-family G member 2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Approved indications
- Gout
- Hyperuricemia
Common side effects
Key clinical trials
- Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets (PHASE4)
- Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (PHASE2)
- Normalizing Antibody Detection in First-void Urine
- SGLT2 Inhibition: Uric Acid Excretion Study (PHASE4)
- The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study
- Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction (PHASE4)
- Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (PHASE2)
- Compare the Renal Protective Effects of Febuxostat and Benzbromarone (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |